-
-
-
-
-
-
-
Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling
-
-
-
-
-
-
-
EU approves Acadia's trofinetide for Rett syndrome treatment
-
-
-
-
-
-
-
Acadia Pharma (ACAD) Tops Q2 EPS by 12c ; Offers Guidance
-
-
-
-
-
-
-
Mizuho Reiterates Outperform Rating on Acadia Pharmaceuticals (ACAD)
-
-
-
-
-
-
-
Acadia Pharma (ACAD) Misses Q1 EPS by 3c ; Offers Guidance
-
-
-
-
-
-
-
Acadia Pharmaceuticals plans re-examination after EU rejection of Rett drug
-
-
-
-
-
-
-
Mizuho Upgrades Acadia Pharmaceuticals (ACAD) to Outperform
-
468,189 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

